Establishment Labs Holdings Inc. (NASDAQ:ESTA) Shares Sold by Brown Advisory Inc.

Brown Advisory Inc. reduced its position in Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 1.9% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 2,293,203 shares of the company's stock after selling 45,166 shares during the quarter. Brown Advisory Inc. owned about 7.95% of Establishment Labs worth $93,574,000 as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in the company. Quarry LP purchased a new stake in shares of Establishment Labs during the 4th quarter worth $27,000. Federated Hermes Inc. boosted its stake in shares of Establishment Labs by 3.0% during the 4th quarter. Federated Hermes Inc. now owns 32,720 shares of the company's stock worth $1,507,000 after purchasing an additional 953 shares during the last quarter. Swiss National Bank grew its stake in Establishment Labs by 2.7% in the 4th quarter. Swiss National Bank now owns 38,500 shares of the company's stock worth $1,774,000 after acquiring an additional 1,000 shares during the period. KLP Kapitalforvaltning AS acquired a new position in Establishment Labs in the fourth quarter valued at $161,000. Finally, Hood River Capital Management LLC boosted its position in shares of Establishment Labs by 236.4% in the fourth quarter. Hood River Capital Management LLC now owns 5,920 shares of the company's stock worth $273,000 after acquiring an additional 4,160 shares during the last quarter. 72.91% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Wall Street Zen upgraded Establishment Labs from a "sell" rating to a "hold" rating in a research note on Saturday, June 14th. BTIG Research started coverage on Establishment Labs in a research report on Friday, May 16th. They set a "buy" rating and a $62.00 target price on the stock. Needham & Company LLC reissued a "buy" rating and set a $48.00 price objective on shares of Establishment Labs in a report on Friday, June 13th. Finally, Citigroup lifted their target price on Establishment Labs from $38.00 to $47.00 and gave the stock a "neutral" rating in a research report on Wednesday. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, Establishment Labs currently has a consensus rating of "Moderate Buy" and an average price target of $51.80.

Establishment Labs Stock Performance

Shares of ESTA traded up $1.09 during midday trading on Wednesday, hitting $45.06. 335,842 shares of the stock traded hands, compared to its average volume of 477,533. The company has a debt-to-equity ratio of 5.72, a quick ratio of 2.05 and a current ratio of 3.36. The business's 50 day moving average price is $37.39 and its two-hundred day moving average price is $36.89. The firm has a market capitalization of $1.30 billion, a PE ratio of -14.54 and a beta of 0.80. Establishment Labs Holdings Inc. has a 1-year low of $26.56 and a 1-year high of $52.41.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.13. Establishment Labs had a negative return on equity of 196.25% and a negative net margin of 52.34%. The company had revenue of $41.38 million during the quarter, compared to analysts' expectations of $41.15 million. During the same quarter in the prior year, the business posted ($0.58) earnings per share. The company's revenue for the quarter was up 11.3% compared to the same quarter last year. Equities research analysts predict that Establishment Labs Holdings Inc. will post -2.41 EPS for the current fiscal year.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.